Camurus
593.5 SEK -0.08%7 investors are following this company
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Revenue
1.72B
EBIT %
30.63 %
P/E
76.29
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CAMX
Daily low / high price
590.5 / 599
SEK
Market cap
34.8B SEK
Turnover
27.68M SEK
Volume
47K
Latest videos
Financial calendar
Interim report
2024-07-16
Interim report
2024-11-07
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sandberg Development AB | 37.9 % | 37.9 % |
Fjärde AP-fonden | 4.3 % | 4.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Camurus AB: Förändring av antalet aktier och röster i Camurus
Camurus AB: Ny publikation visar effekt av vecko- och månadsinjektioner av buprenorfin vid behandling av opioidberoende hos individer som använder fentanyl
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Camurus AB: New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
![Camurus, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/18127181-e8fb-44ee-b085-a2fc6302f4df.png)
Camurus, Audiocast with teleconference, Q2'24
Camurus AB: Exercise of Camurus' employee stock options program 2021/2024
Camurus AB: Inlösen av Camurus personaloptionsprogram 2021/2024
Camurus AB: Camurus styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt Prestationsaktieprogram 2024/2027
Camurus AB: Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2024/2027
Camurus AB: Camurus to present at Jefferies 2024 Healthcare Conference New York
Camurus AB: Camurus presenterar vid Jefferies 2024 Healthcare Conference New York
Camurus AB: Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly
Camurus AB: Camurus ansökan om marknadsgodkännande för oktreotid månadsdepå (CAM2029) för akromegali har accepterats för granskning av EMA
Camurus AB: Resolutions at the annual general meeting 2024 in Camurus
Camurus AB: Beslut vid Camurus årsstämma 2024
![Camurus, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/4f691bda-1f84-4756-a385-94b7afc6bb54.png)